CMV infection in heart transplant recipients
Conditions
Brief summary
The rate of early CMV infections/disease during virostatic prophylaxis.
Detailed description
•The rate of leukopenia during virostatic prophylaxis, •The rate of neutropenia during virostatic prophylaxis, •The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter., •The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis, •The rate of CMV resistance to virostatic therapy.
Interventions
Sponsors
University Medical Center Ljubljana
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of early CMV infections/disease during virostatic prophylaxis. | — |
Secondary
| Measure | Time frame |
|---|---|
| •The rate of leukopenia during virostatic prophylaxis, •The rate of neutropenia during virostatic prophylaxis, •The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter., •The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis, •The rate of CMV resistance to virostatic therapy. | — |
Countries
Slovenia
Outcome results
None listed